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Abstract: Metformin is an antihyperglycemic agent commonly used for the treatment of Type II diabetes mellitus. How-
ever, its effects on patients are derived usually from clinical experiments. In this study, a dynamic model of Type II diabe-
tes mellitus with the treatment of metformin is proposed. The Type II diabetic model is a modification of an existing com-
partmental diabetic model. The dynamic simulation of the metformin effect for a Type II diabetic patient is based on the 
pharmacokinetic and pharmacodynamic relationship with a human body. The corresponding model parameters are esti-
mated by optimization using clinical data from published reports. Then, the effect of metformin in both intravenous and 
oral administration on a Type II diabetes mellitus model are compared. The combination treatment of insulin infusion plus 
oral metformin is shown to be superior than the monotherapy with oral metformin only. These results are consistent with 
the clinical understanding of the use of metformin. For further work, the model can be analyzed for evaluating the treat-
ment of diabetes mellitus with different pharmacological agents. 
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1. INTRODUCTION 
Diabetes mellitus is a metabolic disorder caused by either 
insufficient insulin production in islet cells in the pancreas or 
by tissue resistance against secreted insulin, which leads to 
excessive glucose concentration in the blood. Since 1961, the 
mathematical  modeling  of  glucose-insulin  interaction  in  a 
normal body has been studied [1]. Some physiologic models 
use anatomical organs and tissue compartments to propose a 
method for simulating glucose metabolism and its regulation 
by insulin and glucagons in a healthy body [2, 3]. Their main 
application was to simulate the physiological dynamics for 
Type I diabetic patients and analyze the control system for 
blood glucose level regulation [4, 5]. Vahidi  et al. (2010) 
recently  proposed  a  substantial  modification  of  the 
compartmental model for Type II diabetic patients who were 
characterized  by  multiple  abnormalities  in  the  pancreas, 
body  tissues  and  liver  [6].  The  proposed  model  did  not 
include any medication effect except insulin. 
Metformin has been used as a glucose-lowering agent in 
Type II diabetes mellitus since 1957. Nearly 40 years later, it 
was  approved  in  the  United  States  and  rapidly  gained 
worldwide acceptance [7-9]. In recent years, pharmacokinetic 
-  pharmacodynamic  (PK-PD)  modeling  has  become  a  key 
factor in modern drug discovery and development [10]. The 
use of PK-PD modeling in translational drug research is a 
promising approach that provides better understanding of the  
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underlying  kinetic  phenomena  involved  with  the  study  of 
absorption, distribution, metabolism and excretion of drugs. 
There  are  continuing  efforts  to  develop  the  PK  and  PD 
models  in  order  to  optimize  therapy.  D'Argenio  and 
Schumitzky (1979) published software to estimate parameters 
for the PK models [11], Stepensky et al. (2001) presented the 
plasma glucose-lowering effect for oral metformin treatment 
in diabetic rats [12], and Pentikainen et al. (1979) described 
the pharmacokinetics of the plasma metformin concentration 
in  healthy  volunteers  [13].  Lee  and  Kwon  (2004)  also 
developed  a  PK-PD  model  to  describe  the  relationship 
between plasma concentration of metformin and its glucose-
lowering  effect  based  on  the  study  of  healthy  volunteers 
[14].  In  preliminary  investigations  from  the  literature,  the 
glucose-lowering  effect  of  metformin  is  apparently 
composed of a combination of several distinct activities in 
various  organs  and  tissues  [15,  16],  including  the  liver, 
gastrointestinal tract, blood and tissues [17]. 
However, all of these studies focused on the efficacy and 
safety of metformin based on experimental studies. Because 
of  many  limitations  in  carrying  out  human  experimental 
studies, a dynamic modeling approach of combining the PK-
PD  model  of  metformin  with  the  Type  II  diabetic  patient 
model  is  the  objective  of  this  research.  In  this  modeling 
approach, both the mode of intravenous administration and 
oral  administration  are  considered.  Since  the  combined 
treatment of insulin infusion and oral hypoglycemic agents 
(OHA) is often used in moderate-to-severe Type II diabetic 
patients with secondary failure of OHA [18], the proposed 
model  will be  analyzed to compare  the monotherapy with 
metformin  only  and  the  combination  treatment  of  insulin 
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This  paper  will  first  describe  the  development  of  the 
dynamic model, followed by a comparison of the simulated 
results and human clinical data obtained from literature. 
2. MODELING 
The modeling of metformin in a human body follows the 
idea of compartmental modeling of diabetic patients [6]. The 
human body is represented by seven physiologic  compart- 
ments as shown in Fig. (1). Each block represents a different 
compartment,  except  the  periphery  block,  which  includes 
muscles and body tissues, and the gut compartment which 
contains  the  gastrointestinal  (GI)  lumen  and  GI  wall.  The 
solid lines indicate the blood flow directions, and the point-
dash lines indicate the distribution of metformin. The model 
of  Type  II  diabetic  patients  also  includes  seven  similar 
compartments.  Model  equations  comprise  mass  balance 
equations  of  insulin,  glucose,  and  glucagon  for  each 
compartment. The glucose-lowering effect of metformin  is 
composed  of  a  combination  of  distinct  activities  in  three 
organs and tissues [19], which are the gut, the liver and the 
periphery.  Therefore  a  multi-compartmental  PK  model  is 
used to describe the pharmacokinetics of metformin. 
2.1.  Type  II  Diabetic  Model  and  the  Treatment  of 
Metformin 
The  physiological  model  for  Type  II  diabetic  patients 
used here is based on the compartmental model proposed by 
Vahidi  et  al.  (2010)  [6].  The  proposed  model  contains  a 
number of variables calculated to represent the behavior of a 
Type II diabetic patient with no metformin effect, including 
the  concentration  of  insulin,  glucose,  glucagons,  and  the 
metabolic rate of different compartments. 
With the treatment of metformin , the metabolic rate of 
different substances are adjusted according to their specific 
effects.  Based  on  the  clinical  literature,  the  effects  of 
metformin  mainly  include:  increased  rate  of  intestinal 
glucose consumption [20]; decreased hepatic glucose output 
[21];  and  increased  glucose  uptake  by  muscle  cells  and 
adipocytes [22]. 
For  the  simulation  of  Type  II  diabetic  patients 
administered  with  metformin,  the  metabolic  rates  of  the 
above mentioned effects of metformin are modified. The rest 
of the Type II diabetic model is based on the one developed 
by Vahidi et al. (2010), and its parameters remain the same 
as originally proposed (2010). 
As metformin is known to increase glucose consumption 
by the gut, the rate of gut glucose consumption (rGGU
PK PD ) in 
the Type II diabetic model is modified as shown in eq. (1), 
rGGU
PK PD =(1+ EGI)rGGU                (1) 
where  rGGU  is the rate of the gut glucose consumption with 
no  metformin  effect,  and  EGI   is  a  weight  coefficient  that 
represents  the  increment  of  the  rate  rGGU   following  the 
administration of metformin. Similarly, metformin is known 
to lower hepatic glucose production, whose rate ( rHGP
PK PD ) is 
modified as shown in eq. (2), 
rHGP
PK PD =(1  EL)rHGP                (2) 
where  rHGP   is  the  rate  of  the  hepatic  glucose  production 
without the effect of metformin for Type II diabetic patients, 
and  EL  is a weight coefficient that indicates the inhibition of 
glucose  production  in  the  liver  (L).  Also,  the  rate  of  the 
periphery  glucose  uptake  ( rPGU
PK PD )  is  modified  to  the 
following equation: 
rPGU
PK PD =(1+ EP)rPGU                (3) 
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where  rPGU   is  the  rate  of  the  periphery  glucose  uptake 
without  the  treatment  of  metformin,  and  EP   is  a  weight 
coefficient  that  indicates  the  stimulation  of  glucose 
consumption in the periphery (P) with the metformin effect. 
The  overall  glucose-lowering  effect  of  metformin 
involves the stimulation of glucose consumption in the GI 
tract  and  periphery  ( EGI   and  EP )  and  the  inhibition  of 
glucose production in the liver (EL ). These three coefficients 
EGI ,  EL , and  EP  represent the glucose-lowering effect in the 
corresponding compartments, and can be calculated through 
the pharmacokinetic-pharmacodynamic analysis of metformin. 
2.2. PK-PD Model 
A  PK-PD  model  is  used  to  describe  the  relationship 
between the amount of metformin and its glucose-lowering 
effect for Type II diabetic patients after intravenous and oral 
administration.  Based  on  previous  analysis,  the  PK-PD 
model  of  metformin  for  the  treatment  of  Type  II  diabetes 
mellitus  constitutes  three  compartments  including  the  gut, 
liver and periphery as shown in Fig. (1). 
The accumulation of metformin in the GI wall is not only 
through the GI lumen, but also via arterial blood supply to 
the intestine (with the rate constant  kpg ). Therefore, in the 
gut  compartment,  both  the  GI  lumen  and  GI  wall  are 
accounted  into  the PK  modeling. A multicompartment PK 
model is used to describe the pharmacokinetics of metformin 
[11].  The  following  mass  balance  equations  can  be  easily 
derived for different compartments, 
dX1 /dt =  X1(kgo + kgg)+ XO              (4) 
dX2 /dt = X1kgg + X4kpg   X2kgl              (5) 
dX3 /dt = X2kgl + X4kpl   X3klp              (6) 
dX4 /dt = X3klp   X4(kpl + kpg + kpo)+ XI            (7) 
where  X1,  X2 ,  X3 , and  X4  are the mass of metformin in 
the GI lumen, GI wall, liver, and periphery compartments, 
respectively.  XO  is the flow rate of metformin as a result of 
a single oral ingestion, and  XI  is the flow rate of metformin 
from intravenous infusion. The rate constants are:  kgo , drug 
elimination via the fecal route;  kgg , drug transfer from the 
GI  lumen  to  the  GI  wall  compartment;  kgl ,  drug  transfer 
from the GI wall to the liver compartment;  klp  and  kpl , drug 
transfer from the liver to the periphery compartment and vice 
versa;  kpg , drug transfer from the periphery to the GI wall 
compartment;  and  kpo ,  drug  elimination  via  the  urination 
route. As shown in eq. (4)-(7), the equations are written in 
terms of metformin amounts and not concentrations, thereby 
avoiding  the  need  for  estimating  the  volumes  of  the  PK 
compartments.  In  this  case,  the  metformin  plasma 
concentrations  are  calculated  as  the  mass  of  metformin 
divided  by  the  blood  flow  (20.9 ± 4.1  ml/min/kg  body 
weight) [23].  
 In this modeling approach, metformin is distributed to 
the GI lumen,  liver,  and periphery compartment following 
oral  and  intravenous  modes  of  administration.  The 
compartmental model with first-order absorption is used to 
describe the kinetics of the intravenous administration. The 
flow  rate  of  metformin  XI   following  the  intravenous 
administration is represented by 
XI = Ae
  t + Be
  t +Ce
  t               (8) 
where  XI  is the flow rate of metformin at the end of the 
infusion; and    ,     and     are the parameters that indicate 
the rate constants during the exponential phases;  A,  B and 
C  are the parameters that represent the contribution of the 
corresponding exponentials. These parameters are estimated 
by optimization using experimental data points.  
For  the  oral  administration,  the  pharmacokinetics  of 
metformin from mouth to the GI lumen is described by the 
following equation: 
XO = A
'e
  't   B
'e
  't                (9) 
where  
'  and  
'  are rate constants;  A
'  and  B
'  represent the 
contribution  of  the  corresponding  exponentials.  These 
parameters  are  also  estimated  by  optimization  using 
experimental data points. 
As  indicated  in  eqs.  (4)-(9),  the  transient  changes  of 
metformin amounts at different biophases can be obtained. 
To  generate  the  overall  glucose-lowering  effect  of 
metformin, a PK-PD model is proposed in eqs. (10)-(12). As 
mentioned  previously,  the  glucose-lowering  effect  of 
metformin mainly includes three compartments, of which the 
metabolic rate of the gut glucose consumption ( rGGU
PK PD ) is 
only  attributed  to  the  GI  wall.  According  to  the  literature 
published by Stepensky et al. (2001) [12], the corresponding 
weight  coefficients  in  three  compartments  ( EGI ,  EL ,  and 
EP ) are calculated as follows: 
EGI =
 GI,max  (X2)
nGI
( GI,50)
nGI +(X2)
nGI
            (10) 
EL =
 L,max  (X3)
nL
( L,50)
nL +(X3)
nL
             (11) 
EP =
 P,max  (X4)
nP
( P,50)
nP +(X4)
nP
             (12) 
where     is the parameter representing the maximum effect 
of  metformin  in  each  compartment  ( GI,max ,   L,max ,  and 
 P,max );  GI,50,  L,50 , and  P,50  are the mass of metformin at 
the biophase that produces 50% of its maximal effect; and 
nGI ,  nL , and  nP  are the shape factors. The model parameter 
estimation  is  an  iterative  process,  and  the  parameters  are 
fitted  with  the  published  data  set  from  the  literature 
published by Stepensky et al. (2002) [19]. 
The  glucose-lowering  effect  of  metformin  in  each 
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The metabolic rates of their corresponding compartment in 
eqs.  (1)-(3)  are  modified  accordingly.  The  behavior  of  a 
Type II diabetic patient with the treatment of metformin is 
presented through the combination of the PK-PD model and 
the Type II diabetic model proposed by Vahidi et al. (2010). 
3. RESULTS AND DISCUSSION 
The  dynamic  simulation  for  the  combined  model  is 
programmed  in  Matlab  and  the  model  parameters  are 
optimized by using clinical data. The mass of metformin and 
metformin plasma concentrations are calculated for both the 
intravenous  administration  and  oral  administration.  The 
relationship  between  metformin  amounts  and  the  glucose-
lowering effect is then obtained through solving the set of 
equations (eqs. (4)-(12)). Using the glucose-lowering effect 
( EGI ,  EL , and  EP ), the metabolic rate of the corresponding 
compartment for a Type II diabetic patient with the treatment 
of metformin ( rGGU
PK PD ,  rHGP
PK PD , and  rPGU
PK PD ) is modified, and 
the simulation results are compared with the set of clinical 
data  tested  from  Type  II  diabetic  patients  following  the 
combination  treatment  of  insulin  infusion  plus  oral 
metformin [18]. 
3.1. Plasma Metformin Concentration 
For  the  mode  of  intravenous  administration,  a  set  of 
experimental  data  from  healthy  volunteers  with  a  mean 
weight of 60.3 kg published by Pentikainen et al. (1979) [13] 
is used to optimize the model parameters. In this test, 500 
mg of metformin was infused into a cubital vein over 5 min. 
After the intravenous infusion, blood samples were collected 
in heparinized tubes at 0, 5, 10, 15, 20, 30, 45 min and 1, 1.5, 
2, 3, 4, 5, 6, 8, and 10 h. For the mode of oral administration, 
a  set  of  data  obtained  from  twenty-two  healthy  male 
volunteers  with  a  mean  weight  of  68  kg  via  the  oral 
metformin  treatment  published  by  Lee  and  Kwon  (2004) 
[14] is used to adjust the parameters of the PK model. In this 
test, the 500 mg metformin tablet was given orally with 240 
mL water. The blood samples were collected at the following 
time points: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h. 
Plasma  metformin  concentrations  were  determined  by 
validated high performance liquid chromatography (HPLC) 
method. Through the optimization, the parameters of the PK-
PD model are estimated and shown in Table 1. 
In  eqs.  (4)-(7),  the  rate  constants  ( k )  indicate  the 
pharmacokinetics of metformin between each compartment, 
which  are  very  difficult  to  be  measured  directly  from  a 
human  body  in  a  clinically  acceptable  manner.  For  these 
constants, only rats data were found in the literature. These 
rat  experiments  were  designed  to  mimic  the  plasma  drug 
concentrations  versus  time  profile  with  metformin 
administrations in different organs. Therefore in this paper, 
the  corresponding  rate  constants  are  estimated  from 
streptozotocin  diabetic  rats  reported  by  Stepensky  (2002) 
[19]. By substituting these rate constants and the parameters 
in  Table  1  into  eqs.  (4)-(9),  the  mass  of  metformin  are 
calculated. Then, the plasma concentrations of metformin are 
calculated as the mass of metformin divided by the blood 
flow. In this case, the blood flow is the reported blood flow 
(20.9 ml/min/kg body weight) [23] multiplied by the mean 
weight of volunteers in clinical tests (60.3 kg and 68 kg) [13, 
14]. Both the plasma concentrations of metformin and the 
clinical  data  from  healthy  volunteers  are  graphically 
represented in Fig. (2). 
In  Fig.  (2a),  after  the  intravenous  administration  of 
metformin,  the  plasma  metformin  concentration  increases 
rapidly and then decays exponentially. The half-life in this 
figure is 1.7 hours calculated by Stepensky (2002) [19]. The 
pharmacokinetics of  metformin following  an oral adminis- 
tration is characterized by a flip-flop mode signifying a much 
slower rate of absorption than renal elimination. The time it 
takes for metformin to reach the peak concentration in the 
oral administration is about 2 hours as shown in Fig. (2b). 
The simulation results are well fitted with the clinical data, 
and  indicate  distinct  rates  of  elimination  of  metformin  in 
each of these two modes of administration. The trends are 
consistent  with  clinical  understanding  of  pharmacokinetic 
characteristics of metformin. 
Table 1.  Parameters of the PK-PD Model 
PK-PD Parameters         
A  (mcg/min)  1.89e+04    
'   0.1 
B  (mcg/min)  9.45e+03   kgo  ( min
 1 )   1.88e-03 
C  (mcg/min)  1.89e+03   kgg  ( min
 1 )   1.85e-03 
A
'  (mcg/min)  2.70e+04   kgl  ( min
 1 )   0.46 
B
'  (mcg/min)  2.70e+04   klp  ( min
 1 )   0.91 
    12.80   kpl  ( min
 1 )   1.01e-02 
    1.90   kpg  ( min
 1 )   4.13 
    0.40   kpo  ( min
 1 )   0.51 
 
'   0.06       
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3.2. Plasma Glucose and Insulin Concentration 
The relationship between the mass of metformin and the 
glucose-lowering  effect  is  based  on  the  PK-PD  model  as 
described  in  the  earlier  section  (eqs.  (10)-(12)),  and  the 
metabolic  rate  of  the  corresponding  compartment  is  then 
modified. For both intravenous and oral administrations, the 
glucose-lowering effects are shown in Fig. (3). 
In  Fig.  (3),  for  the  intravenous  administration,  the 
maximum glucose-lowering effect of the periphery is about 
45%; and for the oral administration, it is about 40% in the 
GI  compartment.  These  results  are  similar  to  the 
experimental results obtained by Lee and Kwon (2004) [14]. 
The dynamic simulation of a Type II diabetic patient with 
the treatment of metformin is performed using the physio- 
logical model proposed by Vahidi et al. (2010) considering 
the modification of the metabolic rate ( EGI ,  EL , and  EP ). 
According  to  the  clinical-experimental  data  published  by 
Pentikainen et al. (1979) and Lee and Kwon (2004), 500 mg 
of metformin is the dosage used in the dynamic model for 
both  intravenous  and  oral  administrations.  A  50g  meal  is 
implemented after drug administration, and the mathematical 
representation  of  the  meal  sub-model  is  described  in 
Lehmann and Deutsch (1992) [24].  
 The  simulation  results  of  glucose  concentrations 
following the intravenous and oral administrations are shown 
in Fig. (4). Since the clinical data are measured from healthy 
human [13, 14], comparing them with the simulated diabetic 
data is not appropriate. Instead, the dynamic simulation of a 
Type  II  diabetic  patient  with  no  metformin  effect  was 
performed to compare with the effect of metformin for Type 
II diabetic patients.  
In  Fig.  (4),  by  the  treatment  of  metformin  the  plasma 
glucose  concentration  is  obviously  lowered.  There  is  no 
significant  difference  in  plasma  glucose  concentration 
between  the  intravenous  administration  and  oral  adminis- 
tration.  The  peak  plasma  glucose  concentration  with  no 
metformin  effect  is  around  250  mg /dl   which  is  reached 
after 2 hours. For both modes of metformin administration, 
the peak plasma glucose concentrations are attained 2 hours 
after  the  drug  administration.  Compared  with  the  clinical 
data  published  by  Stepensky  [12]  and  Pala  [18],  the 
simulated  peak  plasma  glucose  concentrations  and  the 
corresponding time are reasonable. 
Based on the Type II diabetic model with and without the 
meftormin treatment, the plasma insulin concentration can be 
calculated as shown in Fig. (5). Since the metabolic rate of 
the corresponding compartment is effected by the treatment 
of metformin, the plasma insulin concentration is lowered. 
For both the intravenous and oral administration, the trends 
of the palsma insulin concentration are characterized by  a 
flip-flop  mode.  Usually,  metformin  effects  the  glucose 
metabolic rates directly  and then distributed  to  the  insulin 
 
Fig. (2). Clinical and simulated plasma metformin concentration for healthy subjects who received 500 mg metformin by a) intravenous and 
b) oral administration. 
 
Fig. (3). The glucose-lowering effect of metformin (500 mg) in the corresponding organ following a) intravenous and b) oral administration. 
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which  would  result  in  a  peak  value  around  3  hours.  The 
simulation  results  indicate  a  peak  plasma  insulin  concen- 
tration  for  a  Type  II  diabetic  patient  with  no  metformin 
effect around 11.8  mU /l , while the corresponding value for 
the  Type II diabetic patient following the intravenous and 
oral administration is lowered to 10.9  mU /l  and 11  mU /l  
respectively.  
As shown in Figs. (4 and 5), both the plasma glucose and 
insulin  concentrations  are  lowered  significantly  after  the 
treatment  of  metformin.  By  comparing  the  mode  of  intra- 
venous administration and oral administration, no significant 
difference is found in the plasma glucose-lowering effect. 
3.3. Combination Treatment of Insulin Infusion Plus Oral 
Metformin 
To verify the proposed model and compare the different 
modes  of  metformin  treatments,  the  simulation  of  basal 
insulin in combination with metformin treatment for type II 
diabetic  patients  is  performed.  A  set  of  published  data 
obtained  from  testing  Type  II  diabetic  patients  (aged 
65.0 ± 3.9  years,  body  mass  index  27.7 ± 3.8  kg/m
2 ) 
following the combination treatment of insulin infusion plus 
oral metformin is used. In this set of data, all patients firstly 
received  human  insulin  (0.1  U/kg)  before  breakfast,  lunch 
and  dinner,  plus  metformin  (500  mg)  after  meals.  Blood 
glucose was measured before and at 30 min intervals for 3 h 
after a standard meal [18]. Based on the proposed model, the 
simulated results are compared with the published data (see 
Fig. 6). 
In Fig. (6), for the combination treatment using both 500 
mg  of  metformin  and  0.1  U/kg  of  insulin,  the  simulated 
results are consistent with the clinical data reported by Pala 
et al. (2007) [18]. 
Based  on  the  proposed  model,  different  modes  of 
treatments are compared, including: Treatment A, single oral 
metformin  (500  mg);  Treatment  B,  single  insulin  infusion 
(0.1  U/kg);  Treatment  C,  the  basal  insulin  (0.1  U/kg)  in 
combination  with  metformin  (500  mg);  Treatment  D,  the 
basal  insulin  (0.05  U/kg)  in  combination  with  metformin 
(750  mg);  Treatment  E,  the  basal  insulin  (0.15  U/kg)  in 
combination with metformin (250 mg). The simulated results 
are  presented  in  Fig.  (7).  It  can  be  seen  that  the  plasma 
glucose concentrations for Type II diabetic patients following 
combination treatments are obviously lower than monothera- 
pies.  Compared  with  the  monotherapy  of  meformin  alone 
(Treatment A), the monotherapy of insulin alone (Treatment 
B)  is  better.  For  combination  treatments,  no  significant 
 
Fig. (4). Plasma glucose concentration of type II diabetic patients 
who  received  500mg  of  metformin  by  intravenous  and  oral 
administrations. 
 
Fig. (5). Plasma insulin concentration of type II diabetic patients. 
 
Fig. (6). Plasma glucose concentrations for Type II diabetic patients 
following the combination treatment of insulin (0.1 U/kg) infusion 
plus oral metformin (500 mg). 
 
Fig. (7). Plasma glucose concentrations for Type II diabetic patients 
following five modes of treatments and the tested data from Type II 
diabetic patients following the combination treatment. 
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differences in the value of plasma glucose concentrations are 
found for the different amount of metformin and insulin. 
Consequently, the simulation results clearly show that the 
model  is  able  to  properly  describe  the  dynamics  of  using 
metformin. The effects of the combination treatment using 
both metformin and insulin infusion are significantly better 
than the monotherapy of metformin or insulin alone. 
4. CONCLUSIONS AND FUTURE WORK 
In present work, a PK-PD model of metformin has been 
developed for a Type II compartmental diabetic model. The 
plasma  metformin  concentration  and  the  glucose-lowering 
effect  on  the  corresponding  compartments  have  been 
demonstrated  by  comparing  the  predicted  outcomes  with 
clinical data. The plasma glucose and insulin concentrations 
have  been  calculated  for  both  intravenous  and  oral 
administrations. Using the proposed models, different modes 
of treatments are compared directly. As a result, the effects 
of  monotherapies  are  demonstrated  worse  than  the 
combination  therapy  with  both  metformin  and  insulin.  By 
incorporating the effects of other antihyperglycemic agents 
for Type II diabetes mellitus,  the model can be useful for 
evaluating the treatment of diabetes mellitus with different 
pharmacological agents. 
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